We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05060666
Recruitment Status : Not yet recruiting
First Posted : September 29, 2021
Last Update Posted : November 2, 2021
Sponsor:
Collaborator:
GKM Gesellschaft für Therapieforschung mbH
Information provided by (Responsible Party):
Infectopharm Arzneimittel GmbH

Tracking Information
First Submitted Date  ICMJE September 28, 2021
First Posted Date  ICMJE September 29, 2021
Last Update Posted Date November 2, 2021
Estimated Study Start Date  ICMJE November 2021
Estimated Primary Completion Date March 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 28, 2021)
COVID-19 disease [ Time Frame: Day 14 ]
Occurrence of a COVID-19 disease up to the final visit (day 14), defined as the presence of the clinical condition according to the RKI case definition (acute respiratory symptoms of any severity OR new loss of smell and taste occurred OR illness-related death) AND a positive SARS-CoV-2 PCR test on the day the symptoms were determined (+/- 4 days)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 28, 2021)
  • Adverse events and side effects [ Time Frame: 14 days ]
    Number and severity of adverse events and side effects.
  • Type, number and severity of symptoms [ Time Frame: 14 days ]
    Type, number and severity of symptoms within the 14-day of study on subjects suffering from COVID-19 (incl. hospitalization, oxygen saturation and demand, intensive care treatment)
  • Severity of the COVID-19 disease [ Time Frame: 14 days ]
    Severity of the COVID-19 disease according to the investigator's assessment
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]
Official Title  ICMJE Placebo-controlled Randomized Double-blind Phase III Study on the Efficacy and Safety of Ivermectin Tablets (Driponin®) for the Prophylaxis of COVID-19 Disease in Adult Contact Persons Living in the Household of a Person Suffering From COVID-19 [German: Placebo-kontrollierte Randomisierte Doppel-blinde Phase III Studie Zur Wirksamkeit Und Sicherheit Von Ivermectin Tabletten (Driponin®) für Die Prophylaxe Der COVID-19 Erkrankung Bei im Haushalt Lebenden Erwachsenen Kontaktpersonen Einer an COVID-19 Erkrankten Person]
Brief Summary The Prevent-COVID study is a prospective, multicenter, randomized, two-armed, placebo-controlled, double-blind, interventional study in which the efficacy and safety of ivermectin in COVID-19 post-exposure prophylaxis (PEP) is examined in adult, close family contacts living in the household of a subject suffering from COVID-19.
Detailed Description

Study population and study sites:

The study is carried out in about 30 private practices or clinics in Germany that regularly carry out SARS-CoV-2 PCR tests and treat COVID-19 patients.

Adult close contact persons of newly diagnosed COVID-19 patients living in the same household are considered for participation.

Study duration and assessment:

The study will last 14 days, in which the following study-specific measures will be undertaken:

  • Documentation of demographics (age, gender, ethnicity, height and weight, degree of relationship to the COVID-19 patient)
  • Documentation of current comorbidities
  • Documentation of current medical accompanying measures
  • Documentation of the general condition
  • Vital signs
  • COVID-19 symptoms
  • SARS-CoV-2 PCR test: Only for medical confirmation of the presence of COVID-19 symptoms during an unplanned COVID-19 visit or final visit.
  • Subject diary (daily measurement of body temperature, contact intensity with the index person)
  • Pregnancy test in women of childbearing potential

Objectives:

Primary Objective: To demonstrate the efficacy of ivermectin in the COVID-19 post-exposure prophylaxis of adult contact persons living in the household of a person suffering from COVID-19 (index person)

Secondary objectives:

  • To demonstrate the safety of ivermectin in the COVID-19 post-exposure prophylaxis of adult contact persons living in the household of a person suffering from COVID-19 (index person)
  • To determine the severity of the symptoms of subjects suffering from COVID-19 during the study period and the comparison between the ivermectin and the placebo group.

IMP: Driponin® is an approved drug with the active ingredient Ivermectin, used to treat parasitic infections. One tablet Driponin® contains 3 mg Ivermectin. As part of the clinical trial, the medicinal product will be examined with regard to indication, dosage and application schedule deviating from the intended purpose and the package insert.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Condition  ICMJE Covid19
Intervention  ICMJE
  • Drug: Ivermectin

    2 doses of Ivermectin will be administered with 48 hours time interval.

    The dosage is based on body weight calculated as follows:

    • 15 mg for 40-60 kg = 5 tablets à 3 mg
    • 18 mg for 60-80 kg = 6 tablets à 3 mg
    • 24 mg for > 80 kg = 8 tablets à 3 mg each

    This corresponds to an ivermectin dose of about 300 µg / kg.

    Other Names:
    • Driponin
    • ATC-code P02CF01
    • Substance code SUB12089MIG
  • Drug: Placebo

    An analogous number of tablets is administered for placebo:

    • 5 tablets for 40-60 kg
    • 6 tablets for 60-80 kg
    • 8 tablets for > 80 kg

    The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin.

Study Arms  ICMJE
  • Experimental: Ivermectin
    2 doses of ivermectin at day 0 and day 2
    Intervention: Drug: Ivermectin
  • Placebo Comparator: Placebo
    2 doses of placebo at day 0 and day 2
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: September 28, 2021)
412
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 2022
Estimated Primary Completion Date March 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • age of at least 18 years
  • adult subject living in the same household as a related COVID-19 patient (index person)

Exclusion Criteria:

  • index person has COVID-19 symptoms for more than 5 days at enrolment
  • known past COVID-19 or current infection confirmed by positive SARS-CoV-2 PCR test at enrolment
  • symptoms at enrolment indicating COVID-19: increased body temperature OR acute respiratory symptoms of any severity OR newly occuring loss of taste or smell OR ague OR sumulatneously occuring headache and body ache
  • known contraindications to the use of the study medication (in alignemnt with current summary of product characteristics of Driponin®)
  • known chronic obstructive pulmonary disease
  • known acute or chronic hepatitis B or C or other clinically recognizable or known liver dysfunction
  • known HIV infection or AIDS
  • known symptomatic allergic rhinitis
  • current (inlcuding up to 24 hours before enrolment) or planned (during next 14 days) therapy with non-steroidal anti-inflammatory drugs, other pain medication (e.g., ASS (including prophylactic use), metamizol)
  • recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic steroids
  • recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic immunosuppressive drugs
  • known or clinically suspected disturbance of the blood-brain-barrier (e.g., ABCB-1 (=MDR1) mutation) as well as history of neurotoxic effects by ivermectin or other substrates/inhibitors of the para-glycoprotein (P-gp)
  • known hypersensitivity/intolerance to the study drug or any of its exicpients, in particular ivermectin, microcrystalline cellulose, pre-agglutinated starch, butyl hydroxyanisole or magnesium stearate
  • pregnancy or lactation
  • women of child-bearing potential planning to become pregnant or not using effective mehods of contraception
  • any other severe disorder, which in the opinion of the investigator would preclude the subject from trial participation
  • previous or planned (during next 14 days) vaccination with any COVID-19 vaccine
  • recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with Ivermectin
  • recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with drugs with evident or potential benefit in treating COVID-19 in alignemnt with RKI
  • apparent unreliability or lack of compliance (e.g., not willing to orally administer the required number of tablets on 2 days or not willing to complete the subject diary during 14 days)
  • known alcohol or drug abuse
  • participation in another clinical trial during the last 30 days or planned participation in another clinical trial during the next 30 days
  • previous participation in this same clinical trial
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05060666
Other Study ID Numbers  ICMJE PREVENT-COVID
2021-002445-15 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Infectopharm Arzneimittel GmbH
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Infectopharm Arzneimittel GmbH
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE GKM Gesellschaft für Therapieforschung mbH
Investigators  ICMJE Not Provided
PRS Account Infectopharm Arzneimittel GmbH
Verification Date November 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP